Stryker Corporation (SYK)

This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.

SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Stryker (SYK). But which of these two stocks offers value investors a better bang for ...

As robotic-assisted surgery becomes a cornerstone of modern healthcare, two medtech giants — Intuitive Surgical ISRG and Stryker SYK — are leading the charge. Intuitive, the pioneer behind the da Vinc...

Get a deeper insight into the potential performance of Stryker (SYK) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some ...

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bank of America, Chevron, Stryker, Value Line and Sypris are included in this Analyst Blog.

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors ...

Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.

SYK unveils next-gen Mako SmartRobotics, revolutionizing hip, knee and spine surgeries with greater precision and first-to-market robotic hip revision technology.